Prix FOB
Obtenir le dernier prix120 ~ 200 USD / Case ( Negotiable )
|1 Pack Minimum Order
Pays:
South Africa
N ° de modèle:
-
Prix FOB:
120 ~ 200 USD / Case ( Negotiable ) Obtenir le dernier prix
Localité:
South africa
Prix de commande minimale:
120 per Case
Commande minimale:
1 Pack
Packaging Detail:
4 injections per pack
Heure de livraison:
3 to 7 days
Capacité de Fournir:
-
Payment Type:
T/T, Western Union
Groupe de produits :
Personne àcontacter Mr. James
60 COMMANDO RD INDUSTRIAL WEST JOHANNESBURG, JOHANNESBURG, GAUTENG
----------
INDICATIONS AND USAGE --------------------------- MOUNJAROâ„¢ is a
glucose-dependent insulinotropic polypeptide (GIP) receptor and
glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an
adjunct to diet and exercise to improve glycemic control in adults
with type 2 diabetes mellitus. (1) Limitations of Use: • Has not
been studied in patients with a history of pancreatitis (1, 5.2) •
Is not indicated for use in patients with type 1 diabetes mellitus
(1) ------------------------DOSAGE AND
ADMINISTRATION----------------------- • The recommended starting
dosage is 2.5 mg injected subcutaneously once weekly (2.1) • After
4 weeks, increase to 5 mg injected subcutaneously once weekly (2.1)
• If additional glycemic control is needed, increase the dosage in
2.5 mg increments after at least 4 weeks on the current dose. • The
maximum dosage is 15 mg subcutaneously once weekly (2.1). •
Administer once weekly at any time of day, with or without meals.
(2.2) • Inject subcutaneously in the abdomen, thigh, or upper arm.
(2.2) • Rotate injection sites with each dose.
----------------------DOSAGE FORMS AND
STRENGTHS--------------------- Injection: 2.5 mg, 5 mg, 7.5 mg, 10
mg, 12.5 mg, or 15 mg per 0.5 mL in single-dose pen (3)
INDICATIONS AND USAGE MOUNJAROâ„¢ is indicated as an adjunct to diet
and exercise to improve glycemic control in adults with type 2
diabetes mellitus. Limitations of Use • MOUNJARO has not been
studied in patients with a history of pancreatitis [see Warnings
and Precautions (5.2)]. • MOUNJARO is not indicated for use in
patients with type 1 diabetes mellitus. 2 DOSAGE AND ADMINISTRATION
2.1 Dosage • The recommended starting dosage of MOUNJARO is 2.5 mg
injected subcutaneously once weekly. The 2.5 mg dosage is for
treatment initiation and is not intended for glycemic control. •
After 4 weeks, increase the dosage to 5 mg injected subcutaneously
once weekly. • If additional glycemic control is needed, increase
the dosage in 2.5 mg increments after at least 4 weeks on the
current dose. • The maximum dosage of MOUNJARO is 15 mg injected
subcutaneously once weekly. • If a dose is missed, instruct
patients to administer MOUNJARO as soon as possible within 4 days
(96 hours) after the missed dose. If more than 4 days have passed,
skip the missed dose and administer the next dose on the regularly
scheduled day. In each case, patients can then resume their regular
once weekly dosing schedule
| Pays: | South Africa |
| N ° de modèle: | - |
| Prix FOB: | 120 ~ 200 / Case ( Negotiable ) Obtenir le dernier prix |
| Localité: | South africa |
| Prix de commande minimale: | 120 per Case |
| Commande minimale: | 1 Pack |
| Packaging Detail: | 4 injections per pack |
| Heure de livraison: | 3 to 7 days |
| Capacité de Fournir: | - |
| Payment Type: | T/T, Western Union |
| Groupe de produits : | Beauty |
